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Abstract
Aim Analysis of the hypothesis that 22% of breast cancer
cases detected by screening mammography would disap-
pear spontaneously.
Methods Critical appraisal of the relevant scientific litera-
ture using established methods.
Results The hypothesis—although it is unusual—seems to
be very well supported by data from several independent
research groups and justifies three lessons.
Conclusions First, it is necessary to complete the last step
of the concept of traditional evidence-based medicine
(EBM), i.e., to confirm that the outcome that is predicted
by scientific evidence will also be observed in daily clinical
practice. Second, the focus of medical teaching should be
directed to final clinical outcomes and patient benefit rather
than surrogate parameters, such as completed procedures or
test results. Third, the availability of data to answer
unsolved questions may become a more important indicator
for high-quality health-care systems than the performance
of services of unknown incremental value.
Keywords Spontaneous remissions . Breast cancer .
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Introduction
Norwegian epidemiologists (Zahl et al. 2008) presented a
study that is different from classical evidence-based studies:
it is neither randomized nor is it presenting a better test or
treatment. This study seriously challenges what we know
about breast cancer. It questions our concept on the natural
course of the disease, the effectiveness of breast cancer
screening as well as of breast cancer therapy. If the result of
this study is confirmed, it may be considered one of the first
examples of ‘confirmation-based medicine.’ The authors of
this pivotal study assume that 22% of breast cancer cases
will regress spontaneously (Zahl et al. 2008).
Several steps are necessary to make progress
Several challenging steps were necessary to phrase the final
hypothesis that a considerable portion of breast cancer
cases might regress spontaneously. This final hypothesis
was triggered by a simple but critical question Zahl and his
colleagues asked. They concluded that the high compliance
with breast cancer screening in Norway and Sweden (about
80%) should result in an increased breast cancer incidence
rate. Second, the increased incidence rate of breast cancer
in younger women should be accompanied by a
corresponding decrease of breast cancer incidence in
elderly women. This second hypothesis is the really
important part of the considerations.
As Zahl and his colleagues could not confirm the second
hypothesis, they postulated in their 2004 papers that “the
level of overdiagnosis in nationwide mammography screen-
ing is much higher than previously thought” (Zahl et al.
2004b). Swedish scientists reported data similar to those of
Zahl et al., but derived a different interpretation. They
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concluded that their previous interpretation (Jonssone et al.
2005) on a long-term reduction of breast cancer mortality
by 26-30% was confirmed by the actual results (Jonsson et
al. 2007). When reanalysing Jonsson's data (Jonsson et al.
2005), Zahl and Maehlen (2006) concluded that 73% of the
“latent cancers” are no longer detectable at the mammo-
grams of women at age 70. Zahl and Mæhlen published the
hypothesis that some of these latent cancers may regress
spontaneously already in 2004 (Zahl et al. 2004a). Later on
they described the incidence rates of breast cancer of two
groups of women ages 50 to 64 in two overlapping 6-year
periods (Zahl et al. 2008). One group of 109,784 women
was followed from 1992 to 1997. Mammography screening
in Norway was initiated in 1996. In 1996 and 1997, all
women of this group were offered a single mammogram
within this 2-year period, and about 80% accepted. The
second group of 119,472 women was followed from 1996
to 2001. All were offered mammograms every 2nd year in
this 6-year period, i.e., three mammograms, and about 80%
accepted. It was expected that the two groups would have
roughly the same number of breast cancers, either detected
at the end or found along the way. Instead, 22% more
cancers were detected in women who had routine screen-
ings every 2nd year (Table 1). The most important possible
pitfalls of this comparison of non-randomized cohorts were
discussed and, for example, the magnitude of differential
use of hormone replacement therapy was calculated. The
comparison is fair. Not this observation, but its interpreta-
tion was revolutionary: these additional cancers will not
affect the women's life if neglected. As this “new idea”
absolutely contradicts the present understanding of cancer
biology, most clinicians will reject it. There are two
additional steps that have to be completed before this
potential scientific progress can be transferred from bench
to bedside.
First, scientific reports that contradict the “state of the art”
have to convince referees and editors of scientific journals as
there will be no progress without publication. According to a
“biologic law”, papers that contradict mainstream thinking
have a higher chance to be rejected by referees and editors
than those that agree. Our previous editorial (Porzsolt et al.
2003a, b) pointed out that the acceptance or rejection of
scientific evidence is a “subjective” decision. There are not
many examples to support this “biologic law”: an earlier
report of Zahl et al. was withdrawn from one journal (2006a)
and subsequently published in another (2006b). When we
(Kaplan and Porzsolt 2008) scrutinized the actual publication
of Zahl (2008), we concluded that there are more data that
corroborate than contradict this hypothesis.
& There are data from randomized studies on mammog-
raphies that confirm Zahl's hypothesis (Miller et al.
1992, 2000, 2002; Zackrisson et al. 2006).
& It can clearly be demonstrated that some breast cancer
patients benefit from treatment, but the proportion of
breast cancer patients who survive for unknown reasons
is much bigger than the proportion in whom survival is
clearly related to the treatment. The recent results of the
Early Breast Cancer Trialists' Collaborative Group
(EBCTGC 2008) confirmed that systemic treatment
reduces the 10-year breast cancer mortality from 32% to
24% in women younger than 50 years and from 42% to
36% in women 50-69 years. These numbers include
three important messages: About 30% of all women
with detected breast cancer will die despite of treatment.
Almost 10% of treated women (8% of younger women
and 6% of women 50-69 years of age) benefit from
systemic treatment, and finally, 60% of women with
breast cancer will survive without systemic treatment.
There are no valid estimates on the proportion of breast
cancer patients who survive due to local treatment such
as surgery.
& Spontaneous remissions are known in many tumours
such as metastatic melanoma and renal cell cancer, in
neuroblastoma and in precancerous lesions of colon and
cervix cancer (for examples, see Zahl et al. 2008).
& Zahl et al. (2008) could demonstrate that the difference
between the experimental and the control group in their
study was neither related to an improved quality of the
Norwegian cancer registry, nor to differences between
the experimental and the control group, nor to an
improving sensitivity of mammography, nor to a
temporal increase in the incidence caused by external
factors such as hormone replacement therapy, and
finally,
& in contrast, Zahl's results may even underestimate the
spontaneous remission rates as opportunistic screening
could not be avoided in the control group, and the
compliance with the screening program was 80%, but
not 100% in the experimental group.






every 2nd year over 6-year period
Control group: One mammogram
at end of 6-year period
Relative risk
screened/control
50-64 55-69 1,909 1,564 1.22 (1.16-1.30)
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Second, it is not sufficient to convince the referees and
editors of a scientific journal, but the scientific community
has to accept the new concept. There are several examples
that demonstrate that it takes about a decade to translate an
innovation from bench to bedside. We showed for testicular
cancer that the delayed use of cisplatin for more than 10
years may have resulted in more then 1,000 avoidable
deaths (Hölzel and Altwein 1991).
Third, once a statement or a guideline has been accepted
by the scientific community, it is essential that scientists
keep reanalyzing this ‘state of the art’. New knowledge
may emerge and may challenge a traditional statement or
guideline. The performance indicator no. 14 of the
European guidelines for quality assurance in breast cancer
screening and diagnosis (Perry et al. 2006) requests that the
breast cancer detection rate, expressed as a multiple of the
underlying, expected breast cancer incidence rate (IR) in
the absence of screening should be 1.5-fold of the IR in
subsequent regular screening examinations. This require-
ment is probably based on the assumption that any
additionally detected cancer will be associated with benefit
for the patient. In the context of the new data, this
conclusion may be reanalysed. The new version of the
European guideline may request that screening should not
detect more cancer, but the existing cancer earlier.
Progress to whom
There are several natural hurdles that prevent the accep-
tance of a new idea by the general population. Doctors who
provide a particular service, industries that produce the
needed products, insurance companies that offer a particular
service and politicians who are expected to guarantee the
best possible health care will have considerable difficulties
to change from the traditional concept to the new idea. The
same will happen to affected women.
Mammography is probably the most frequently used and
the most investigated of all screening methods. According
to the actual state of the art, mammography is recommen-
ded by medical societies and politicians and is strongly
demanded by women (Schwartz et al. 2004) despite of the
known rates of false-positive and false-negative test results
and the high number of persons needed to screen (1,000-
2,000) to prevent one death due to breast cancer (Gøtzsche
and Nielsen 2006).
The real problem with screening is the appraisal rather
than the assessment: The effect of screening is not a random
effect, but is statistically significant. In absolute numbers
almost 1 per mille of womens' lifes can be saved by
screening. The problem is the appraisal of this value of
screening. Most women believe the political message that
says that breast cancer screening would reduce breast
cancer mortality by 20%. The scientific message is that
the relative but not the absolute risk reduction is 20%.
Nobody knows if women will continue to demand breast
cancer screening and how many societies will be willing to
pay for breast cancer screening if they know that the true
effect of screening is less than 1‰ instead of 20%. There
will be a tremendous discussion when it is realized that
breast cancer screening is the most investigated screening
method and is probably better supported by scientific
evidence than any other screening in adult medicine.
Possible explanations for this strong demand may be
related to ‘perceived safety’, which is highly dependent on
the provided information. We discussed this concept of
‘perceived safety’ in breast cancer patients (Porzsolt et al.
2006b) and are aware that the concept of perceived safety
may be risky if it keeps patients from using effective
treatments. But it may be helpful if perceived safety
Table 2 Goals, methods and results of traditional evidence-based medicine (EBM) and the proposed confirmation-based medicine
Evidence-based medicine Confirmation-based medicine
Goals Comparison of new and established therapies under conditions of
a clinical study (comparison of efficacy). Consideration of
internal validity. Results presented from the viewpoint of
clinical epidemiology
Comparison of new and established therapies under everyday
conditions (comparison of effectiveness). Consideration of
external validity. Results presented from the viewpoints of
different stakeholders
Methods Step 1: Definition of characteristics of the study groups (inclusion
and exclusion criteria). Definition of treatment options
Step 1: Patients allocated to different treatment groups
according to preference. All patients are included
Step 2: Random allocation of individual patients to treatment options Step 2: Definition of characteristics of study groups and
consideration of treatment options
Step 3: Evaluation of patients in the groups to which they were
randomized (intention to treat)
Step 3: Classification of patients for evaluation in the
subgroups according to defined criteria and treatment option
Results Comparison of new and established therapies under ideal
conditions. Confirmation of internal validity Requirement for
planning and conduct of health-care research
Testing of results of clinical research under everyday
conditions. Description of external validity. Consideration
of perspectives of different stakeholders
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contributes to managing psychological problems. The
political problem is expressed by the dissonance of the
political recommendation (to screen and to treat) and the
misunderstanding of the scientific message.
Open questions
The message of science is not to avoid screening and
treatment, but rather to keep investigating it in order to
remove the remaining uncertainty. We also need reliable
data on which women will benefit and which will be
harmed by breast cancer screening and treatment. This
challenge can be called “confirmation-based medicine
(CBM)” and corresponds to the last step of the traditional
evidence-based medicine concept proposed by David
Sackett and colleagues (2004). From a different point of
view, one can argue this last step bridges evidence-based
medicine and the developing health-care research (Hay
1999; Porzsolt and Kilian 2006). Differences between
evidence-based medicine and “confirmation-based medi-
cine” (Table 2) may be expressed by differences in goals,
methods and results as proposed earlier (Porzsolt et al.
2005; 2006b).
For breast cancer management these data can be
generated in two ways. First, we should try to convince
all eligible women that only a high participation rate will
generate the data that are needed for the best possible
management. Nevertheless, there will be women who will
reject mammography screening for various reasons. In
order to minimize the negative effects of non-compliance,
we might discuss the anonymous recording of risk factors
of any non-compliant woman at a national data base. If this
collection of information is acceptable from an ethical point
of view, one could improve the quality of screening data by
comparing the baseline risks of compliant and non-
compliant women (Porzsolt 2009).
Second, we have to study appropriate markers that can
widely be applied to identify the subgroups of patients that
will benefit from screening and treatment. Examples of
these markers are described by van de Vijver et al. (2002),
Ghosh et al. (2008) and Harbeck et al. (2008). In Germany,
breast cancer screening began to be offered to the public at
the end of the 1960s. Today we spend € 250-300 million
annually for breast cancer screening. Unfortunately, the
German contribution to the scientific progress in breast
cancer management is rather small. Also, this aspect
deserves reconsideration.
Finally, there are three lesions we can learn from the
Zahl experiment (Zahl et al. 2008). First, there is a need to
extend the concept of traditional evidence-based medicine
(EBM). The renewed aspect may be named outcomes
research or confirmation-based medicine (CBM). The
traditional form of EBM requested scientific evidence to
support the introduction of a new diagnostic tool or
treatment into day-to-day practice. The large mammogra-
phy trials completed in the period of 1960-1990 are
examples of EBM that justified the introduction of
mammography screening. The Zahl experiment is an
example of outcomes research or CBM: it tries to confirm
in day-to-day practice that has been recommended by
EBM. EBM was the first of two necessary steps. It was the
evidence-based recommendation to introduce an innova-
tion. CBM represents the continuation of these steps. It is
the evidence-based confirmation that the innovation is
really doing what it promised to do.
Second, we might teach our students the principles of
outcomes research in addition to the principles of EBM.
Similar objective procedures were introduced by the
Japanese Bank of International Cooperation (JBIC) for
Confirmation of Environmental and Social Considerations
to ensure its compliance with guidelines (Japan Finance
Cooperation 2003). We tried to offer such a strategy in
medicine that we called ‘clinical economics’. Both outcomes
research and ‘clinical economics’ follow the same strategy.
They are concerned about the value of medicine from the
patients' point of view. This strategy may become an
important topic in medical schools (Porzsolt and Kilian
2006).
Third, the ability of a health-care system to provide the
data that are needed to answer questions like those raised
by Zahl et al. may, in the future, be considered an important
indicator for the quality of a national health-care system.
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